Scientists map immune landscape of liver tumors to predict cancer return
NCT ID NCT07564908
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 64 patients with colorectal cancer that spread to the liver and was surgically removed. Researchers are analyzing tumor samples to see how different immune cells and growth patterns relate to survival and cancer recurrence. The goal is to better understand why some patients do better than others.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help doctors better predict outcomes and tailor treatments for colorectal cancer that has spread to the liver.
- What could go wrong
- This is an observational study analyzing tissue samples, not testing a new treatment. It may not lead to direct patient benefits or changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 64 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2018
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study enrolled patients with CRLM who underwent R0 resection.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with CRLM who underwent R0 resection * Histologically or cytologically confirmed CRLM * Have sufficient liver metastasis tissue specimens available for analysis * Complete treatment and follow-up records Exclusion Criteria: * Patients did not undergo R0 resection * Postoperative specimens were unavailable * Clinical data were incomplete.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal neoplasms are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a computer model read MRI scans to predict which liver cancer patients will relapse?
- AI reads tumor slides to match cancer patients with trials
- Targeted drug combo takes aim at hard-to-treat KRAS-mutant colorectal cancer
- Flushing the right colon Mid-Procedure: a new way to catch hidden polyps?
- Replacing the whole liver: a radical bid to outlast colorectal cancer
- Can a platform trial match the right drug combo to each tumor?